A call for more with a desire for less: Pelvic radiotherapy with androgen deprivation in the treatment of prostate cancer

Journal of Clinical Oncology

Volumn 21, Issue 10, 2003, Pages 1899-1901

  Pollack, Alan ^a  

^a FOX CHASE CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PROSTATE SPECIFIC ANTIGEN; ANTIANDROGEN;

ANDROGEN THERAPY; CANCER ADJUVANT THERAPY; CANCER GROWTH; CANCER RELAPSE; CANCER RISK; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; EDITORIAL; GASTROINTESTINAL TOXICITY; HUMAN; METASTASIS; MORBIDITY; PRIORITY JOURNAL; PROSTATE CANCER; RANDOMIZED CONTROLLED TRIAL; TREATMENT FAILURE; COMPUTER ASSISTED RADIOTHERAPY; DRUG ADMINISTRATION; MALE; MULTIMODALITY CANCER THERAPY; NOTE; PATHOLOGY; PELVIS; PHASE 3 CLINICAL TRIAL; PROSTATE TUMOR;

ANDROGEN ANTAGONISTS; CLINICAL TRIALS, PHASE III; COMBINED MODALITY THERAPY; DRUG ADMINISTRATION SCHEDULE; HUMANS; MALE; PELVIS; PROSTATIC NEOPLASMS; RADIOTHERAPY, CONFORMAL; RANDOMIZED CONTROLLED TRIALS;

EID: 0037674073     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2003.01.129     Document Type: Editorial

References (24)

1. Roach M III, Desilvio M, Lawton C, et al: Phase III trial comparing whole pelvis versus prostate only radiotherapy and neoadjuvant versus adjuvant combined androgen suppression: Radiation Therapy Oncology Group 9413. J Clin Oncol 21:1904-1911, 2003
2. Pilepich MV, Winter K, John MJ, et al: Phase III radiation therapy oncology group (RTOG) trial 86-10 of androgen deprivation adjuvant to definitive radiotherapy in locally advanced carcinoma of the prostate. Int J Radiat Oncol Biol Phys 50:1243-1252, 2001
3. Stock RG, Ferrari AC, Stone NN: Does pelvic irradiation play a role in the management of prostate cancer? Oncology (Huntingt) 12:1467-1476, 1998
4. Pan CC, Kim KY, Taylor JM, et al: Influence of 3D-CRT pelvic irradiation on outcome in prostate cancer treated with external beam radiotherapy. Int J Radiat Oncol Biol Phys 53:1139-1145, 2002
5. Gardner BG, Zietman AL, Shipley WU, et al: Late normal tissue sequelae in the second decade after high dose radiation therapy with combined photons and conformal protons for locally advanced prostate cancer. J Urol 167:123-126, 2002
6. Bolla M, Gonzalez D, Warde P, et al: Improved survival in patients with locally advanced prostate cancer treated with radiotherapy and goserelin. N Engl J Med 337:295-300, 1997
7. Hanks G, Lu J, Machtay M, et al: RTOG protocol 92-02: A phase III trial of the use of long-term total androgen suppression following neoadjuvant cytoreduction and radiotherapy in locally advanced carcinoma of the prostate. Int J Radiat Oncol Biol Phys 48:112, 2000
8. Sanguineti G, Agostinelli S, Foppiano F, et al: Adjuvant androgen deprivation impacts late rectal toxicity after conformal radiotherapy of prostate carcinoma. Br J Cancer 86:1843-1847, 2002
9. Cox J, Grignon D, Kaplan R, et al: Consensus statement: Guidelines for PSA following radiation therapy-American Society for Therapeutic Radiology and Oncology Consensus Panel. Int J Radiat Oncol Biol Phys 37:1035-1041, 1997
10. Zietman AL, Prince EA, Nakfoor BM, et al: Androgen deprivation and radiation therapy: Sequencing studies using the Shionogi in vivo tumor system. Int J Radiat Oncol Biol Phys 38:1067-1070, 1997
11. Joon DL, Hasegawa M, Sikes C, et al: Supraadditive apoptotic response of R3327-G rat prostate tumors to androgen ablation and radiation. Int J Radiat Oncol Biol Phys 38:1071-1077, 1997
12. Pollack A, Salem N, Ashoori F, et al: Lack of prostate cancer radiosensitization by androgen deprivation. Int J Radiat Oncol Biol Phys 51:1002-1007, 2001
13. Granfors T, Modig H, Damber J, et al: Combined orchiectomy and external radiotherapy versus radiotherapy alone for nonmetastatic prostate cancer with or without pelvic lymph node involvement: A prospective randomized study. J Urol 159:2030-2034, 1998
14. Lawton CA, Winter K, Murray K, et al: Updated results of the phase III Radiation Therapy Oncology Group (RTOG) trial 85-31 evaluating the potential benefit of androgen suppression following standard radiation therapy for unfavorable prognosis carcinoma of the prostate. Int J Radiat Oncol Biol Phys 49:937-946, 2001
15. Bolla M, Collette L, Blank L, et al: Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): A phase III randomised trial. Lancet 360:103-106, 2002
16. Hanlon AL, Horwitz EM, Hanks GE, et al: Short term androgen deprivation and PSA doubling time: Their relationship to one another and to disease progression following radiation therapy for prostate cancer. Int J Radiat Oncol Biol Phys 54:136-136, 2002 (abstr)
17. Granfors T, Tomic R, Bergh A, et al: After radiotherapy testosterone stimulation is unable to increase growth in the dunning R3327-PAP prostate tumour. Urol Res 27:357-361, 1999
18. Kaminski JM, Hanlon A, Lim Joon D, et al: The effect of sequencing of androgen ablation and radiation on prostate cancer growth. Int J Radiat Oncol Biol Phys 54:190-191, 2002
19. Pollack A, Zagars GK, Starkschall G, et al: Prostate cancer radiation dose response: Results of the M. D. Andersen phase III randomized trial. Int J Radiat Oncol Biol Phys 53:1097-1105, 2002
20. Heidenreich A, Varga Z, Von Knobloch R: Extended pelvic lymph-adenectomy in patients undergoing radical prostatectomy: High incidence of lymph node metastasis. J Urol 167:1681-1686, 2002
21. Clark T, Parekh DJ, Cookson MS, et al: Randomized prospective evaluation of extended versus limited lymph node dissection in patients with clinically localized prostate cancer. J Urol 169:145-147, 2003
22. Zagars GK, Pollack A, von Eschenbach AC: Management of unfavorable locoregional prostate carcinoma with radiation and androgen ablation. Cancer 80:764-775, 1997
23. Zagars GK, Pollack A, von Eschenbach AC: Addition of radiation therapy to androgen ablation improves outcome for subclinically node-positive prostate cancer. Urology 58:233-239, 2001
24. Pollack A, Kuban DA, Zagars GK: Impact of androgen deprivation therapy on survival in men treated with radiation for prostate cancer. Urology 60:22-30, 2002